Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Statins Affect Skeletal Muscle Performance

Published: Fri, 23 Mar 2018 12:00:00 EDT
Find out how muscle function and exercise performance are impacted among patients receiving statin treatment.
Journal of Clinical Endocrinology & Metabolism

HBcrAg: An Emerging Marker for Chronic HBV Infection

Published: Fri, 23 Feb 2018 12:00:00 EST
Review the potential clinical application of hepatitis B core-related antigen, which has been proposed as a serum marker for disease monitoring and prognostication of chronic hepatitis B infection.
Alimentary Pharmacology & Therapeutics

Gemcitabine Plus Sirolimus for Osteosarcoma

Published: Fri, 23 Feb 2018 12:00:00 EST
The combination of gemcitabine and sirolimus may be a safe and effective option for patients with relapsed unresectable osteosarcoma.
Annals of Oncology

A Newborn in Acute Respiratory Distress: USMLE Question

Published: Fri, 23 Feb 2018 12:00:00 EST
A newborn male infant is admitted to the neonatal intensive care unit with acute respiratory distress. What condition is likely associated?
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


Merck's ERK inhibitor shows promise in combo against resistant cancers

Published: Thu, 22 Feb 2018 19:12:51 +0000
One-fifth of patients in a phase 1 study responded to Merck's ERK inhibitor, a comparable response rate to other cancer drugs, such as MEK inhibitors. The results suggest the drug could be used in tandem with another to fight cancers with a specific mutation.

A personalized MS treatment built from skin stem cells

Published: Thu, 22 Feb 2018 14:05:22 +0000
Scientists at the University of Cambridge believe they’ve found a new way to repair the damaged myelin around nerve cells that's characteristic of multiple sclerosis—and it involves reprogramming patients’ own skin cells.

Deal-hungry Takeda forges another R&D alliance

Published: Thu, 22 Feb 2018 13:28:33 +0000
Takeda has added another early-stage research partnership as it reboots its R&D operations, this time teaming up with two Seattle-based academic centers in a project focused on its key targets of cancer, gastrointestinal disease and neurological disorders.

Gilead, Sangamo strike $3B off-the-shelf CAR-T deal

Published: Thu, 22 Feb 2018 13:23:02 +0000
Gilead’s Kite has struck a $3 billion deal to access Sangamo Therapeutics’ zinc finger nuclease (ZFN) technology. Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position as a long-term front-runner in the growing cell therapy space.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy